MENU

Matthew R. Zibelman, MD

Matthew Zibelman, MD

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Assistant Professor, Department of Hematology/Oncology

Kidney, Bladder, and Prostate Cancer TRDG Member

Research Program

Treatment Philosophy

I am a medical oncologist specializing in the treatment of genitourinary cancers.  As a medical oncologist, I work with patients at all phases of malignant disease, which allows me the opportunity to join patients and families on a journey that can be at times both exhilarating and exhausting.  I understand that the patient-oncologist relationship is a unique partnership and one that I take seriously.  The journey of cancer provides access to moments in life that can be emotionally challenging for all parties, and I view my role as one ultimately about providing information and guidance to help navigate the path in the way best suited to each patient.

I find genitourinary oncology to be a particularly satisfying and exciting field within medical oncology.  It includes a diverse group of patients and a variety of different disease with their own unique opportunities and challenges.  It is an area involved in a great deal of research, which has afforded new treatment options for patients, and allows me to be involved in helping patients live longer, live better, and in some instances, even help cure them of their disease.    

Fortunately, at Fox Chase Cancer Center, our faculty and staff are dedicated and united towards one goal – optimally treating patients with cancer.  I completed my oncology training at Fox Chase and was fortunate to be able to continue as an attending physician at this world-class institution.  As part of Fox Chase, our patients have access to the cutting edge of clinical oncology, including the ability to have access to exciting new drugs as part of clinical trials.  Medical oncology is a rapidly evolving world, with new treatments and possibilities continually being made available to improve patient outcomes, and Fox Chase strives to remain at the forefront of those changes. 

Education and Training

Educational Background

  • Fellow, Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Resident, Internal Medicine, University of Illinois at Chicago Medical Center, Chicago, IL
  • MD, Lewis Katz School of Medicine, Temple University, Philadelphia, PA

Memberships

  • Society for Immunotherapy of Cancer
  • American Society of Clinical Oncology
  • American Society of Hematology
Patient Stories

Tom Maguire

Bladder Cancer

Tom Maguire

Bladder Cancer

"In 2018 I was diagnosed with muscle invasive bladder cancer, which seemed like it would end my diving, but also provided me a new way to give back."

John Mullarkey, Jr.

Prostate Cancer

John Mullarkey, Jr.

Prostate Cancer

I have always been proactive about my health and started having annual prostate exams when I turned 50 in 2007. My first report was great and showed that my PSA level was undetectable.

Research Profile

Research Program

Research Interests

  • Genitourinary Oncology
  • Melanoma
  • Immunotherapy
Publications

Selected Publications

Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM. Update on perioperative systemic therapy for urothelial carcinoma. Clinical advances in hematology & oncology : H&O, 17(3):176-83, 2019.

Zibelman M, Mehra R. Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell cancer of the head and neck. Am J Clin Oncol. Mar 2016. PubMed

Zibelman M, Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. Oncology. 2016 Feb; 30(2): 160-2. PubMed

Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016 Feb 16;4:8. PubMed

Zibelman M, Wong YN, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.  Investigational New Drugs. June 20, 2015. PubMed

Zibelman M, Wong YN, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.  Investigational New Drugs. 2015 Oct; 33 (5): 1040-7.  PubMed

Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM . A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report from the ClinicalTrials.gov Website. Clinical Genitourinary Cancer. 2015 Apr; 13(2):142-9. PubMed

Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune Checkpoint Blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discovery Medicine.  2014 Dec; 18 (101):341-50. PubMed

Zibelman M, Xiang Q, Muchka S, Nickoloff S, Marks S. Assessing Prognostic Documentation and Accuracy Amongst Palliative Care Clinicians. Journal of Palliative Medicine. 2014, May; 17(5) 521-26. PubMed

Zibelman M, Olszanski A. Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma. Journal of the National Comprehensive Cancer Network.  Vol. 12, supp.  Sept 2014. JNCCN

Additional Publications

MyNCBI

Ratings

174 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.9
  • 4.9
  • 4.9
  • 5.0
  • 4.8

35 PATIENT COMMENTS

  • 5.0
    June 25, 2020
    Dr. Z. very clear about issues, needs and treatments, gives me complete confidence in postponing treatments w/ side-effects while knowing he will tell me when we shouldn't wait any longer.
  • 5.0
    June 11, 2020
    was a telemedicine appt. and went well
  • 5.0
    May 22, 2020
    DR ZIBLEMAN WITH STAFF ALWAYS EXCELLENT. WOULD RECOMMEND HIM
  • 5.0
    May 20, 2020
    Do to the COVID-19 my follow up visit after lab work was conducted over the telephone. Everything was conducted as if I was in the office. Very efficient and through.
  • 5.0
    May 17, 2020
    happy with the I received
  • 5.0
    May 16, 2020
    Visit was a phone conversation due to Corona virus call was excellent
  • 5.0
    May 16, 2020
    Nothing to complain about, could not ask for better.
  • 5.0
    March 23, 2020
    [...] was treated with total concern for me.
  • 5.0
    March 18, 2020
    Dr. Zibelman was very good and followed up with Dr. [...] about my visit.
  • 5.0
    March 18, 2020
    My Dr is excellent ,, FCCC is excellent and the reason I'm alive ,, they care!!!
  • 5.0
    March 04, 2020
    Good experience [...]
  • 5.0
    January 23, 2020
    very goodvery kindvery professional
  • 5.0
    January 19, 2020
    Dr Zibelman the BEST, caring and fine Physician
  • 5.0
    January 09, 2020
    I had two visits with the Doctor, both have been good.
  • 5.0
    November 21, 2019
    Doctor Ziebelman is a terrific doctor. He's knowledgeable, smart, efficient and very compassionate toward me and my wife, who comes with me. We respect his ability and follow his advise. You all are very lucky to have him.
  • 5.0
    November 20, 2019
    Dr. Zibelman is an excellent oncologist. He has my life in his hands...and I'm still here!!
  • 5.0
    October 29, 2019
    Dr. was attentive and informative to my concerns
  • 5.0
    October 24, 2019
    This is the best care that I expect.
  • 5.0
    September 26, 2019
    Dr. Matthew Zibelman and staff are EXTREMELY HELPFUL AND COURTEOUS.
  • 5.0
    September 26, 2019
    All good.
LOAD MORE

Connect with Fox Chase